Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386318095> ?p ?o ?g. }
Showing items 1 to 91 of
91
with 100 items per page.
- W4386318095 abstract "Abstract Background Since the FLOT4-AIO study (2019) showed improved survival in patients treated with neoadjuvant fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) compared to those treated with neoadjuvant anthracycline triplets, FLOT became standard of care in the Netherlands and most Western countries. The aim of this study was to compare the overall survival (OS), pathological response and surgical outcomes of FLOT chemotherapy to anthracycline triplets in the Netherlands, using real-world population level data. Methods Patients diagnosed with resectable (cT2-4a/cTxN0–3/NxM0) gastro-esophageal junction and gastric carcinoma between 2015–2020 were selected from the Netherlands’ Cancer Registry. Patients were included if they received neoadjuvant FLOT or anthracycline triplets whether this was followed by resection or not. OS was calculated from start of neoadjuvant therapy, analyzed using cox regression analysis and adjusted for sex, age, comorbidities, performance status, cT-stage/cN-stage and tumor grade. Secondary outcomes included the pathological complete response (pCR), proportion of patients that fully completed neoadjuvant chemotherapy (100% of scheduled cycles permitting dose reductions), proportion of patients that underwent (radical) surgical resection and proportion receiving adjuvant therapy. Results 778 included patients were treated with FLOT and 913 with anthracycline triplets. Patients treated with FLOT underwent more staging diagnostic laparoscopies (DLS) (73.5% vs. 44.1%, p < 0.0001). Adjusted OS was better after neoadjuvant FLOT (HR = 0.84, 95% CI 0.72–0.98, p = 0.03). 3-year and 5-year OS were 56.4% and 46.6% after FLOT and 52.7% and 45.5% after anthracycline triplets, respectively. A higher proportion of patients treated with FLOT fully completed neoadjuvant chemotherapy (78.5% vs. 73.1%, p = 0.009) and had R0 resections (86.2% vs. 85.2%, p = 0.007). No statistically significant differences were seen in the proportions of patients that underwent resection, received adjuvant therapy, or had pCR. Conclusion Real-world population level data showed better OS of patients treated with FLOT chemotherapy compared to anthracycline triplets. No statistically significant difference was observed in pCR or resection rates. Thus, not every outcome as described in the FLOT4-AIO trial could be reproduced in a real-world population, despite improved staging with DLS in the FLOT group. Divergent baseline characteristics and less intensive neoadjuvant treatments in real-world patients compared to patients in clinical trials may contribute to this discrepancy." @default.
- W4386318095 created "2023-09-01" @default.
- W4386318095 creator A5012050627 @default.
- W4386318095 creator A5020120535 @default.
- W4386318095 creator A5020972269 @default.
- W4386318095 creator A5021822394 @default.
- W4386318095 creator A5025826957 @default.
- W4386318095 creator A5028436331 @default.
- W4386318095 creator A5029196683 @default.
- W4386318095 creator A5031956921 @default.
- W4386318095 creator A5037535575 @default.
- W4386318095 creator A5040612999 @default.
- W4386318095 creator A5064280092 @default.
- W4386318095 date "2023-08-30" @default.
- W4386318095 modified "2023-10-16" @default.
- W4386318095 title "270. PERIOPERATIVE CHEMOTHERAPY FOR OPERABLE GASTRO-ESOPHAGEAL JUNCTION OR GASTRIC CANCER: FLOT VERSUS ANTHRACYCLINE TRIPLETS" @default.
- W4386318095 doi "https://doi.org/10.1093/dote/doad052.109" @default.
- W4386318095 hasPublicationYear "2023" @default.
- W4386318095 type Work @default.
- W4386318095 citedByCount "0" @default.
- W4386318095 crossrefType "journal-article" @default.
- W4386318095 hasAuthorship W4386318095A5012050627 @default.
- W4386318095 hasAuthorship W4386318095A5020120535 @default.
- W4386318095 hasAuthorship W4386318095A5020972269 @default.
- W4386318095 hasAuthorship W4386318095A5021822394 @default.
- W4386318095 hasAuthorship W4386318095A5025826957 @default.
- W4386318095 hasAuthorship W4386318095A5028436331 @default.
- W4386318095 hasAuthorship W4386318095A5029196683 @default.
- W4386318095 hasAuthorship W4386318095A5031956921 @default.
- W4386318095 hasAuthorship W4386318095A5037535575 @default.
- W4386318095 hasAuthorship W4386318095A5040612999 @default.
- W4386318095 hasAuthorship W4386318095A5064280092 @default.
- W4386318095 hasBestOaLocation W43863180951 @default.
- W4386318095 hasConcept C121608353 @default.
- W4386318095 hasConcept C126322002 @default.
- W4386318095 hasConcept C141071460 @default.
- W4386318095 hasConcept C143998085 @default.
- W4386318095 hasConcept C146357865 @default.
- W4386318095 hasConcept C151730666 @default.
- W4386318095 hasConcept C2776694085 @default.
- W4386318095 hasConcept C2776802502 @default.
- W4386318095 hasConcept C2778292576 @default.
- W4386318095 hasConcept C2779742542 @default.
- W4386318095 hasConcept C2780962732 @default.
- W4386318095 hasConcept C2781190966 @default.
- W4386318095 hasConcept C2908647359 @default.
- W4386318095 hasConcept C31174226 @default.
- W4386318095 hasConcept C526805850 @default.
- W4386318095 hasConcept C530470458 @default.
- W4386318095 hasConcept C71924100 @default.
- W4386318095 hasConcept C86803240 @default.
- W4386318095 hasConcept C90924648 @default.
- W4386318095 hasConcept C99454951 @default.
- W4386318095 hasConceptScore W4386318095C121608353 @default.
- W4386318095 hasConceptScore W4386318095C126322002 @default.
- W4386318095 hasConceptScore W4386318095C141071460 @default.
- W4386318095 hasConceptScore W4386318095C143998085 @default.
- W4386318095 hasConceptScore W4386318095C146357865 @default.
- W4386318095 hasConceptScore W4386318095C151730666 @default.
- W4386318095 hasConceptScore W4386318095C2776694085 @default.
- W4386318095 hasConceptScore W4386318095C2776802502 @default.
- W4386318095 hasConceptScore W4386318095C2778292576 @default.
- W4386318095 hasConceptScore W4386318095C2779742542 @default.
- W4386318095 hasConceptScore W4386318095C2780962732 @default.
- W4386318095 hasConceptScore W4386318095C2781190966 @default.
- W4386318095 hasConceptScore W4386318095C2908647359 @default.
- W4386318095 hasConceptScore W4386318095C31174226 @default.
- W4386318095 hasConceptScore W4386318095C526805850 @default.
- W4386318095 hasConceptScore W4386318095C530470458 @default.
- W4386318095 hasConceptScore W4386318095C71924100 @default.
- W4386318095 hasConceptScore W4386318095C86803240 @default.
- W4386318095 hasConceptScore W4386318095C90924648 @default.
- W4386318095 hasConceptScore W4386318095C99454951 @default.
- W4386318095 hasIssue "Supplement_2" @default.
- W4386318095 hasLocation W43863180951 @default.
- W4386318095 hasOpenAccess W4386318095 @default.
- W4386318095 hasPrimaryLocation W43863180951 @default.
- W4386318095 hasRelatedWork W2018864565 @default.
- W4386318095 hasRelatedWork W2040350626 @default.
- W4386318095 hasRelatedWork W2080089765 @default.
- W4386318095 hasRelatedWork W2167735121 @default.
- W4386318095 hasRelatedWork W2348518476 @default.
- W4386318095 hasRelatedWork W2348977736 @default.
- W4386318095 hasRelatedWork W2586050845 @default.
- W4386318095 hasRelatedWork W3040700866 @default.
- W4386318095 hasRelatedWork W4212973790 @default.
- W4386318095 hasRelatedWork W757206253 @default.
- W4386318095 hasVolume "36" @default.
- W4386318095 isParatext "false" @default.
- W4386318095 isRetracted "false" @default.
- W4386318095 workType "article" @default.